We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
-$260M
Cap. Flow
-$71.1M
Cap. Flow %
-2.5%
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
26
Closed
10

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$12.2M
2
SYK icon
Stryker
SYK
+$10.9M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.83M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.51M
5
BDX icon
Becton Dickinson
BDX
+$8.08M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$36.7M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.4M
3
MRK icon
Merck
MRK
+$16.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.4M
5
DHR icon
Danaher
DHR
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Real Estate 3.21%
3 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
101
Intellia Therapeutics
NTLA
$1.58B
$4.23M 0.15%
58,180
– –
STE icon
102
Steris
STE
$22.7B
$4.03M 0.14%
16,669
– –
VRNA
103
DELISTED
Verona Pharma
VRNA
$3.75M 0.13%
751,905
– –
VECT
104
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$3.56M 0.12%
756,502
– –
CRSP icon
105
CRISPR Therapeutics
CRSP
$5.23B
$3.46M 0.12%
55,080
– –
GTHX
106
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.22M 0.11%
423,869
– –
BCRX icon
107
BioCryst Pharmaceuticals
BCRX
$2.29B
$3.2M 0.11%
+196,625
New +$3.15M
TAK icon
108
Takeda Pharmaceutical
TAK
$52.9B
$3.01M 0.11%
210,146
– –
XNCR icon
109
Xencor
XNCR
$1.48B
$3.01M 0.11%
+112,673
New +$3.63M
PTGX icon
110
Protagonist Therapeutics
PTGX
$8.73B
$2.9M 0.1%
122,271
+21,234
+21% +$598K
HR
111
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.86M 0.1%
104,024
– –
XRN
112
Chiron Real Estate Inc
XRN
$465M
$2.85M 0.1%
34,979
– –
XRAY icon
113
Dentsply Sirona
XRAY
$2.86B
$2.83M 0.1%
57,400
– –
MLTX icon
114
MoonLake Immunotherapeutics
MLTX
$1.53B
$2.77M 0.1%
250,000
– –
NBP
115
NovaBridge Biosciences American Depositary Shares
NBP
$191M
$2.64M 0.09%
162,580
– –
PYXS icon
116
Pyxis Oncology
PYXS
$200M
$2.63M 0.09%
708,303
+573,303
+425% +$4.19M
CERE
117
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$2.58M 0.09%
73,681
+32,678
+80% +$954K
AFMD
118
DELISTED
Affimed
AFMD
$2.56M 0.09%
58,604
– –
ARQT icon
119
Arcutis Biotherapeutics
ARQT
$3.26B
$2.54M 0.09%
131,633
– –
MRUS
120
DELISTED
Merus
MRUS
$2.52M 0.09%
95,290
+53,433
+128% +$1.43M
HR icon
121
Healthcare Realty
HR
$7.02B
$2.21M 0.08%
70,662
– –
HOLX
122
DELISTED
Hologic
HOLX
$2.18M 0.08%
28,347
– –
GRTX
123
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.14M 0.08%
898,374
– –
AUPH icon
124
Aurinia Pharmaceuticals
AUPH
$1.92B
$2.01M 0.07%
162,599
– –
PRGO icon
125
Perrigo
PRGO
$1.49B
$1.97M 0.07%
51,224
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Tekla Capital Management held 185 positions worth $2.85B, down 8.4% from $3.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tekla Capital Management's Q1 2022 filing shows 14 new, 26 increased, 26 reduced and 10 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M. The largest sale was Moderna, an estimated $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M.
  • Tekla Capital Management added most to AstraZeneca in Q1 2022, an estimated $12.2M increase.
  • Tekla Capital Management's biggest Q1 2022 reduction was Moderna, cutting an estimated $36.7M.
  • Tekla Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $16.4M.
  • Tekla Capital Management's ten largest holdings make up 36% of its $2.85B portfolio in Q1 2022.
  • Tekla Capital Management opened 14 new positions and closed 10 in Q1 2022.
  • Tekla Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.